Assessment of YFV- and SARS-CoV-2-specific cell-mediated immunity (CMI) by ELISpot and Flow cytometry with ICS was performed as established and described before.18,20 All peptides and reagents were prepared accordingly. The gating strategy used is outlined in Figure S1f.
Do you have any questions about this protocol?
Post your question to gather feedback from the community. We will also invite the authors of this article to respond.